Microglial purinergic signaling in Alzheimer's disease.
Adenosine P1 receptor
Alzheimer’s disease
Microglia
P2
Purinergic signaling
Journal
Purinergic signalling
ISSN: 1573-9546
Titre abrégé: Purinergic Signal
Pays: Netherlands
ID NLM: 101250499
Informations de publication
Date de publication:
24 Jun 2024
24 Jun 2024
Historique:
received:
31
12
2023
accepted:
03
06
2024
medline:
24
6
2024
pubmed:
24
6
2024
entrez:
23
6
2024
Statut:
aheadofprint
Résumé
Alzheimer's disease (AD) is a progressive and fatal neurodegenerative disease. The prevalent features of AD pathogenesis are the appearance of β-amyloid (Aβ) plaques and neurofibrillary tangles, which cause microglial activation, synaptic deficiency, and neuronal loss. Microglia accompanies AD pathological processes and is also linked to cognitive deficits. Purinergic signaling has been shown to play a complex and tight interplay with the chemotaxis, phagocytosis, and production of pro-inflammatory factors in microglia, which is an important mechanism for regulating microglia activation. Here, we review recent evidence for interactions between AD, microglia, and purinergic signaling and find that the purinergic P2 receptors pertinently expressed on microglia are the ionotropic receptors P2X4 and P2X7, and the subtypes of P2YRs expressed by microglia are metabotropic receptors P2Y
Identifiants
pubmed: 38910192
doi: 10.1007/s11302-024-10029-8
pii: 10.1007/s11302-024-10029-8
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : The National Natural Science Foundation of China
ID : No. 82205284
Organisme : The National Natural Science Foundation of China
ID : No. 82205284
Organisme : The National Natural Science Foundation of China
ID : No. 82205284
Organisme : Shaanxi Provincial Natural Science Basic Research Program
ID : 2022JQ-890
Organisme : Shaanxi Provincial Natural Science Basic Research Program
ID : 2022JQ-890
Organisme : Shaanxi Provincial Natural Science Basic Research Program
ID : 2022JQ-890
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Cieślak M, W A (2018) Role of purinergic receptors in the Alzheimer’s disease. Purinergic Sig 14(4):331–344
doi: 10.1007/s11302-018-9629-0
Rani S, D S, Khajuria A et al (2023) Advanced overview of biomarkers and techniques for early diagnosis of Alzheimer’s disease. Cell Mol Neurobiol 43(6):2491–2523
pubmed: 36847930
doi: 10.1007/s10571-023-01330-y
Se Thoe E, F A, Tang YQ, Chamyuang S, Chia AYY (2021) A review on advances of treatment modalities for Alzheimer’s disease. Life Sci 276:119129
pubmed: 33515559
doi: 10.1016/j.lfs.2021.119129
Breijyeh Z, K R (2020) Comprehensive review on Alzheimer’s disease: causes and treatment. Molecules 25(24):578
doi: 10.3390/molecules25245789
Calovi S, M-A P, Sperlágh B (2019) Microglia and the purinergic signaling system. Neuroscience 405:137–147
pubmed: 30582977
doi: 10.1016/j.neuroscience.2018.12.021
Trinh PNH, B J, Hellyer SD et al (2022) Adenosine receptor signalling in Alzheimer’s disease. Purinergic Sig 18(3):359–381
doi: 10.1007/s11302-022-09883-1
Sudduth TL, S F, Nelson PT et al (2013) Neuroinflammatory phenotype in early Alzheimer’s disease. Neurobiol Aging 34(4):1051–9
pubmed: 23062700
doi: 10.1016/j.neurobiolaging.2012.09.012
London A, C M, Schwartz M (2013) Microglia and monocyte-derived macrophages: functionally distinct populations that act in concert in CNS plasticity and repair. Front Cell Neurosci 7:34
pubmed: 23596391
pmcid: 3625831
doi: 10.3389/fncel.2013.00034
Chen Y, C M (2022) Two-faced behavior of microglia in Alzheimer’s disease. Nat Neurosci 25(1):3–4
pubmed: 34815557
doi: 10.1038/s41593-021-00963-w
Heneka MT, C MJ, El Khoury J et al (2015) Neuroinflammation in Alzheimer’s disease. Lancet Neurol 14(4):388–405
pubmed: 25792098
pmcid: 5909703
doi: 10.1016/S1474-4422(15)70016-5
V FD (2006) Purinergic signalling between axons and microglia. Novartis Found Symp 276:253–8 discussion 259-62, 275-81
doi: 10.1002/9780470032244.ch20
IJzerman AP, J K, Müller CE et al (2022) International union of basic and clinical pharmacology. CXII: adenosine receptors: a further update. Pharmacol Rev 74(2):340–372
pubmed: 35302044
pmcid: 8973513
doi: 10.1124/pharmrev.121.000445
Illes P, U H, Chen JF, Tang Y (2023) Purinergic receptors in cognitive disturbances. Neurobiol Dis 185:106229
pubmed: 37453562
doi: 10.1016/j.nbd.2023.106229
Schnurr M, T T, Shin A et al (2004) Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood 103(4):1391–7
pubmed: 14551144
doi: 10.1182/blood-2003-06-1959
B G (2006) Purinergic signalling–an overview. Novartis Found Symp 276:26–48 discussion 48-57, 275-81
doi: 10.1002/9780470032244.ch4
W J (2002) Neuroprotective role of adenosine in the CNS. Pol J Pharmacol 54(4):313–26
Fang KM, Y C, Sun SH et al (2009) Microglial phagocytosis attenuated by short-term exposure to exogenous ATP through P2X receptor action. J Neurochem 111(5):1225–37
pubmed: 19860838
doi: 10.1111/j.1471-4159.2009.06409.x
Liu CC, W N, Chen Y et al (2023) Cell-autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimer’s disease. Nat Immunol 24(11):1854–1866
pubmed: 37857825
doi: 10.1038/s41590-023-01640-9
Färber K, K H (2006) Purinergic signaling and microglia. Pflugers Arch 452(5):615–21
pubmed: 16791619
doi: 10.1007/s00424-006-0064-7
Costenla AR, C R, de Mendonça A (2010) Caffeine, adenosine receptors, and synaptic plasticity. J Alzheimers Dis 20(Suppl 1):S25-34
pubmed: 20182030
doi: 10.3233/JAD-2010-091384
Costenla AR, D M, Canas PM et al (2011) Enhanced role of adenosine A(2A) receptors in the modulation of LTP in the rat hippocampus upon ageing. Eur J Neurosci 34(1):12–21
pubmed: 21615561
doi: 10.1111/j.1460-9568.2011.07719.x
C JF (2014) Adenosine receptor control of cognition in normal and disease. Int Rev Neurobiol 119:257–307
doi: 10.1016/B978-0-12-801022-8.00012-X
Cao C, C J, Lin X et al (2009) Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer’s disease transgenic mice. J Alzheimers Dis 17(3):681–97
pubmed: 19581723
pmcid: 3746074
doi: 10.3233/JAD-2009-1071
Arendash GW, C C (2010) Caffeine and coffee as therapeutics against Alzheimer’s disease. J Alzheimers Dis 20(Suppl 1):S117-26
pubmed: 20182037
doi: 10.3233/JAD-2010-091249
Koscsó B, C B, Selmeczy Z et al (2012) Adenosine augments IL-10 production by microglial cells through an A2B adenosine receptor-mediated process. J Immunol 188(1):445–53
pubmed: 22116830
doi: 10.4049/jimmunol.1101224
Diaz-Hernandez JI, G-V R, León-Otegui M et al (2012) In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer’s disease through GSK3β and secretases. Neurobiol Aging 33(8):1816–28
pubmed: 22048123
doi: 10.1016/j.neurobiolaging.2011.09.040
Sophocleous RA, O L, Sluyter R (2022) The P2X4 receptor: cellular and molecular characteristics of a promising neuroinflammatory target. Int J Mol Sci 23(10):5739
pubmed: 35628550
pmcid: 9147237
doi: 10.3390/ijms23105739
Montilla A, M G, Matute C et al (2020) Contribution of P2X4 receptors to CNS function and pathophysiology. Int J Mol Sci 21(15):5562
pubmed: 32756482
pmcid: 7432758
doi: 10.3390/ijms21155562
Vázquez-Villoldo N, D M, Martín A et al (2014) P2X4 receptors control the fate and survival of activated microglia. Glia 62(2):171–84
pubmed: 24254916
doi: 10.1002/glia.22596
Kanellopoulos JM, A.-d.-S C, RüütelBoudinot S et al (2021) Structural and functional features of the P2X4 receptor: an immunological perspective. Front Immunol 25(12):645834
doi: 10.3389/fimmu.2021.645834
Varma R, C Y, Troncoso J et al (2009) Amyloid-beta induces a caspase-mediated cleavage of P2X4 to promote purinotoxicity. Neuromol Med 11(2):63–75
doi: 10.1007/s12017-009-8073-2
Duveau A, B E, Boué-Grabot E (2020) Implication of neuronal versus microglial P2X4 receptors in central nervous system disorders. Neurosci Bull 36(11):1327–1343
pubmed: 32889635
pmcid: 7674530
doi: 10.1007/s12264-020-00570-y
Hua J, G.d.P E, Linck N et al (2023) Microglial P2X4 receptors promote ApoE degradation and contribute to memory deficits in Alzheimer’s disease. Cell Mol Life Sci 80(5):138
pubmed: 37145189
pmcid: 10163120
doi: 10.1007/s00018-023-04784-x
Wang Y, G Z, Cao Y et al (2006) Lysosomal enzyme cathepsin B is involved in kainic acid-induced excitotoxicity in rat striatum. Brain Res 1071(1):245–9
pubmed: 16409994
doi: 10.1016/j.brainres.2005.10.074
Bergmann P, G.d.P E, Rissiek B et al (2019) Generation and characterization of specific monoclonal antibodies and nanobodies directed against the ATP-gated channel P2X4. Front Cell Neurosci 12(13):498
doi: 10.3389/fncel.2019.00498
Shi Y, H D (2018) Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat Rev Immunol 18(12):759–772
pubmed: 30140051
pmcid: 6425488
doi: 10.1038/s41577-018-0051-1
Parhizkar S, A T, Brendel M et al (2019) Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat Neurosci 22(2):191–204
pubmed: 30617257
pmcid: 6417433
doi: 10.1038/s41593-018-0296-9
Coddou C, S R, Hevia MJ et al (2019) Characterization of the antagonist actions of 5-BDBD at the rat P2X4 receptor. Neurosci Lett 18(690):219–224
doi: 10.1016/j.neulet.2018.10.047
Ase AR, H N, Zaghdane H et al (2015) Identification and characterization of a selective allosteric antagonist of human P2X4 receptor channels. Mol Pharmacol 87(4):606–16
pubmed: 25597706
doi: 10.1124/mol.114.096222
Fortuny-Gomez A, Fountain SJ (2024) Pharmacological differences between human and mouse P2X4 receptor explored using old and new tools. Purinergic Sig. https://doi.org/10.1007/s11302-024-10018-x
Nagel J, Törmäkangas O, Kuokkanen K, El-Tayeb A, Messinger J, Abdelrahman A, Bous C, Schiedel AC, Müller CE (2024) Preparation and preliminary evaluation of a tritium-labeled allosteric P2X4 receptor antagonist. Purinergic Sig. https://doi.org/10.1007/s11302-024-10005-2
Volonté C, A S, Skaper SD et al (2012) P2X7 receptors: channels, pores and more. CNS Neurol Disord Drug Targets 11(6):705–21
pubmed: 22963440
doi: 10.2174/187152712803581137
Tozaki-Saitoh H, T M, Inoue K (2011) Role of purinergic receptors in CNS function and neuroprotection. Adv Pharmacol 61:495–528
pubmed: 21586368
doi: 10.1016/B978-0-12-385526-8.00015-1
Sperlágh B, I P (2014) P2X7 receptor: an emerging target in central nervous system diseases. Trends Pharmacol Sci 35(10):537–47
pubmed: 25223574
doi: 10.1016/j.tips.2014.08.002
Huang Q, Ying J, Yu W, Dong Y, Xiong H, Zhang Y, Liu J, Wang X, Hua F (2024) P2X7 receptor: an emerging target in Alzheimer’s disease. Mol Neurobiol 61(5):2866–2880. https://doi.org/10.1007/s12035-023-03699-9
Aivar P, B C, Di Lauro C et al (2023) TNAP and P2X7R: new plasma biomarkers for Alzheimer’s disease. Int J Mol Sci 24(13):10897
pubmed: 37446074
pmcid: 10342008
doi: 10.3390/ijms241310897
Haass C, K C, Thinakaran G et al (2012) Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med 2(5):a006270
pubmed: 22553493
pmcid: 3331683
doi: 10.1101/cshperspect.a006270
Lauretti E, D O, Praticò D (2020) Glycogen synthase kinase-3 signaling in Alzheimer’s disease. Biochim Biophys Acta Mol Cell Res 1867(5):118664
pubmed: 32006534
pmcid: 7047718
doi: 10.1016/j.bbamcr.2020.118664
Cai Z, Z Y, Zhao B (2012) Roles of glycogen synthase kinase 3 in Alzheimer’s disease. Curr Alzheimer Res 9(7):864–79
pubmed: 22272620
doi: 10.2174/156720512802455386
Martínez-Frailes C, DL C, Bianchi C et al (2019) Amyloid peptide induced neuroinflammation increases the P2X7 receptor expression in microglial cells, impacting on its functionality. Front Cell Neurosci 12(13):143
doi: 10.3389/fncel.2019.00143
Naseri NN, W H, Guo J et al (2019) The complexity of tau in Alzheimer’s disease. Neurosci Lett 13(705):183–194
doi: 10.1016/j.neulet.2019.04.022
Lopes da Silva S, V B, Elemans S et al (2014) Plasma nutrient status of patients with Alzheimer’s disease: systematic review and meta-analysis. Alzheimers Dement 10(4):485–502
pubmed: 24144963
doi: 10.1016/j.jalz.2013.05.1771
Díaz-Hernandez M, dP A, Díaz-Hernandez JI et al (2008) Inhibition of the ATP-gated P2X7 receptor promotes axonal growth and branching in cultured hippocampal neurons. J Cell Sci 121(Pt 22):3717–28
pubmed: 18987356
doi: 10.1242/jcs.034082
Ruan Z, D J, VenkatesanKalavai S et al (2020) P2RX7 inhibitor suppresses exosome secretion and disease phenotype in P301S tau transgenic mice. Mol Neurodegener 15(1):47
pubmed: 32811520
pmcid: 7436984
doi: 10.1186/s13024-020-00396-2
Kinney JW, B S, Murtishaw AS et al (2018) Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement (N Y) 6(4):575–590
doi: 10.1016/j.trci.2018.06.014
Thawkar BS, K G (2019) Inhibitors of NF-κB and P2X7/NLRP3/Caspase 1 pathway in microglia: novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer’s disease. J Neuroimmunol 15(326):62–74
doi: 10.1016/j.jneuroim.2018.11.010
Zhang G, W Z, Hu H et al (2021) Microglia in Alzheimer’s disease: a target for therapeutic intervention. Front Cell Neurosci 24(15):749587
doi: 10.3389/fncel.2021.749587
Wang W, H D, Feng Y et al (2020) Paxillin mediates ATP-induced activation of P2X7 receptor and NLRP3 inflammasome. BMC Biol 18(1):182
pubmed: 33243234
pmcid: 7694937
doi: 10.1186/s12915-020-00918-w
Muñoz-Planillo R, K P, Martínez-Colón G et al (2013) K⁺ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38(6):1142–53
pubmed: 23809161
pmcid: 3730833
doi: 10.1016/j.immuni.2013.05.016
Chiozzi P, S A, Sanz JM et al (2019) Amyloid β-dependent mitochondrial toxicity in mouse microglia requires P2X7 receptor expression and is prevented by nimodipine. Sci Rep 9(1):6475
pubmed: 31019207
pmcid: 6482182
doi: 10.1038/s41598-019-42931-2
McLarnon JG, R J, Walker DG et al (2006) Upregulated expression of purinergic P2X(7) receptor in Alzheimer disease and amyloid-beta peptide-treated microglia and in peptide-injected rat hippocampus. J Neuropathol Exp Neurol 65(11):1090–7
pubmed: 17086106
doi: 10.1097/01.jnen.0000240470.97295.d3
Ryu JK, M J (2008) Block of purinergic P2X(7) receptor is neuroprotective in an animal model of Alzheimer’s disease. Neuroreport 19(17):1715–9
pubmed: 18852683
doi: 10.1097/WNR.0b013e3283179333
Gao M, W M, Green MA et al (2015) Synthesis of [(11)C]GSK1482160 as a new PET agent for targeting P2X(7) receptor. Bioorg Med Chem Lett 25(9):1965–70
pubmed: 25819093
doi: 10.1016/j.bmcl.2015.03.021
Baudelet D, L E, Millet R et al (2015) Involvement of the P2X7 purinergic receptor in inflammation: an update of antagonists series since 2009 and their promising therapeutic potential. Curr Med Chem 22(6):713–29
pubmed: 25515510
doi: 10.2174/0929867322666141212120926
Murphy N, C T, Richardson JC et al (2012) The neuroprotective effect of a specific P2X₇ receptor antagonist derives from its ability to inhibit assembly of the NLRP3 inflammasome in glial cells. Brain Pathol 22(3):295–306
pubmed: 21933296
doi: 10.1111/j.1750-3639.2011.00531.x
Chrovian CC, S.-J A, Peterson AA et al (2018) A dipolar cycloaddition reaction to access 6-methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines enables the discovery synthesis and preclinical profiling of a P2X7 antagonist clinical candidate. J Med Chem 61(1):207–223
pubmed: 29211470
doi: 10.1021/acs.jmedchem.7b01279
Letavic MA, S B, Allison BD et al (2017) 4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-based P2X7 receptor antagonists: optimization of pharmacokinetic properties leading to the identification of a clinical candidate. J Med Chem 60(11):4559–4572
pubmed: 28493698
doi: 10.1021/acs.jmedchem.7b00408
Miras-Portugal MT, Q M, Gil-Redondo JC et al (2019) P2 receptor interaction and signalling cascades in neuroprotection. Brain Res Bull 151:74–83
pubmed: 30593879
doi: 10.1016/j.brainresbull.2018.12.012
Moore CS, A A, Kinsara A et al (2015) P2Y12 expression and function in alternatively activated human microglia. Neurol Neuroimmunol Neuroinflamm 2(2):e80
pubmed: 25821842
pmcid: 4370387
doi: 10.1212/NXI.0000000000000080
Weisman GA, W M, Kong Q et al (2005) Molecular determinants of P2Y2 nucleotide receptor function: implications for proliferative and inflammatory pathways in astrocytes. Mol Neurobiol 31(1–3):169–83
pubmed: 15953819
doi: 10.1385/MN:31:1-3:169
Peterson TS, C J, Wang Y et al (2010) P2Y2 nucleotide receptor-mediated responses in brain cells. Mol Neurobiol 41(2–3):356–66
pubmed: 20387013
pmcid: 3086510
doi: 10.1007/s12035-010-8115-7
Weisman GA, A D, Garrad R et al (2012) Neuroprotective roles of the P2Y(2) receptor. Purinergic Sig 8(3):559–78
doi: 10.1007/s11302-012-9307-6
Erb L, C C, Ajit D et al (2015) P2Y receptors in Alzheimer’s disease. Biol Cell 107(1):1–21
pubmed: 25179475
doi: 10.1111/boc.201400043
Kwon, H.S K et al (2020) Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener 9(1):42
pubmed: 33239064
pmcid: 7689983
doi: 10.1186/s40035-020-00221-2
Wang C, Z S, Cui X et al (2023) The effects of microglia-associated neuroinflammation on Alzheimer’s disease. Front Immunol 22(14):1117172
doi: 10.3389/fimmu.2023.1117172
Kim HJ, A D, Peterson TS et al (2012) Nucleotides released from Aβ₁₋₄₂ -treated microglial cells increase cell migration and Aβ₁₋₄₂ uptake through P2Y₂ receptor activation. J Neurochem 121(2):228–38
pubmed: 22353164
pmcid: 3323761
doi: 10.1111/j.1471-4159.2012.07700.x
Ajit D, W L, Camden JM et al (2014) Loss of P2Y₂ nucleotide receptors enhances early pathology in the TgCRND8 mouse model of Alzheimer’s disease. Mol Neurobiol 49(2):1031–42
pubmed: 24193664
doi: 10.1007/s12035-013-8577-5
Kong Q, P T, Baker O, Stanley E, Camden J, Seye CI, Erb L, Simonyi A, Wood WG, Sun GY, Weisman GA (2009) Interleukin-1beta enhances nucleotide-induced and alpha-secretase-dependent amyloid precursor protein processing in rat primary cortical neurons via up-regulation of the P2Y(2) receptor. J Neurochem 109(5):1300–10
pubmed: 19317852
pmcid: 2710802
doi: 10.1111/j.1471-4159.2009.06048.x
Camden JM, S A, Camden RE et al (2005) P2Y2 nucleotide receptors enhance alpha-secretase-dependent amyloid precursor protein processing. J Biol Chem 280(19):18696–702
pubmed: 15778502
doi: 10.1074/jbc.M500219200
I K (2007) UDP facilitates microglial phagocytosis through P2Y6 receptors. Cell Adh Migr 1(3):131–2
doi: 10.4161/cam.1.3.4937
Anwar S, P V, Rivest S (2020) Microglia purinoceptor P2Y6: an emerging therapeutic target in CNS diseases. Cells 9(7):1595
pubmed: 32630251
pmcid: 7407337
doi: 10.3390/cells9071595
Anwar S, R S (2020) Alzheimer’s disease: microglia targets and their modulation to promote amyloid phagocytosis and mitigate neuroinflammation. Expert Opin Ther Targets 24(4):331–344
pubmed: 32129117
doi: 10.1080/14728222.2020.1738391
Al-Ghraiybah NF, W J, Alkhalifa AE et al (2022) Glial cell-mediated neuroinflammation in Alzheimer’s disease. Int J Mol Sci 23(18):10572
pubmed: 36142483
pmcid: 9502483
doi: 10.3390/ijms231810572
Rajesh Y, K T (2022) Innate immune cell death in neuroinflammation and Alzheimer’s disease. Cells 11(12):1885
pubmed: 35741014
pmcid: 9221514
doi: 10.3390/cells11121885
Milde S, v.T F, Vilalta A et al (2021) Inflammatory neuronal loss in the substantia nigra induced by systemic lipopolysaccharide is prevented by knockout of the P2Y6 receptor in mice. J Neuroinflammation 18(1):225
pubmed: 34635136
pmcid: 8504061
doi: 10.1186/s12974-021-02280-2
Koizumi S, S-M Y, Nasu-Tada K et al (2007) UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature 446(7139):1091–5
pubmed: 17410128
pmcid: 3464483
doi: 10.1038/nature05704
Neher JJ, N U, Hornik T et al (2014) Inhibition of UDP/P2Y6 purinergic signaling prevents phagocytosis of viable neurons by activated microglia in vitro and in vivo. Glia 62(9):1463–75
pubmed: 24838858
pmcid: 4336556
doi: 10.1002/glia.22693
vK I (2024) Pharmacological characterization of P2Y receptor subtypes - an update. Purinergic Sig 20(2):99–108
doi: 10.1007/s11302-023-09963-w
Victor MB, L N, Luna X et al (2022) Lipid accumulation induced by APOE4 impairs microglial surveillance of neuronal-network activity. Cell Stem Cell 29(8):1197–1212
pubmed: 35931030
pmcid: 9623845
doi: 10.1016/j.stem.2022.07.005
Martens YA, Z N, Liu CC et al (2022) ApoE cascade hypothesis in the pathogenesis of Alzheimer’s disease and related dementias. Neuron 110(8):1304–1317
pubmed: 35298921
pmcid: 9035117
doi: 10.1016/j.neuron.2022.03.004
Gómez Morillas A, B V, Lerouet D (2021) Microglia and neuroinflammation: what place for P2RY12? Int J Mol Sci 22(4):1636
pubmed: 33561958
pmcid: 7915979
doi: 10.3390/ijms22041636
Sipe GO, L R, Tremblay MÈ et al (2016) Microglial P2Y12 is necessary for synaptic plasticity in mouse visual cortex. Nat Commun 7(7):10905
pubmed: 26948129
pmcid: 4786684
doi: 10.1038/ncomms10905
Chinnathambi S, D R (2023) Microglia degrade tau oligomers deposit via purinergic P2Y12-associated podosome and filopodia formation and induce chemotaxis. Cell Biosci 13(1):95
pubmed: 37221563
pmcid: 10204346
doi: 10.1186/s13578-023-01028-0
Badimon A, S H, Ayata P et al (2020) Negative feedback control of neuronal activity by microglia. Nature 586(7829):417–423
pubmed: 32999463
pmcid: 7577179
doi: 10.1038/s41586-020-2777-8
Chen X, W Q, Yang J et al (2023) Diagnostic and therapeutic value of P2Y12R in epilepsy. Front Pharmacol 10(14):1179028
doi: 10.3389/fphar.2023.1179028
Kamondi A, G.-D M, Löscher W et al (2024) Epilepsy and epileptiform activity in late-onset Alzheimer disease: clinical and pathophysiological advances, gaps and conundrums. Nat Rev Neurol 20(3):162–182
pubmed: 38356056
doi: 10.1038/s41582-024-00932-4
Donner L, F K, Gremer L et al (2016) Platelets contribute to amyloid-β aggregation in cerebral vessels through integrin αIIbβ3-induced outside-in signaling and clusterin release. Sci Signal 9(429):ra52
pubmed: 27221710
doi: 10.1126/scisignal.aaf6240
Zeng J, W G, Liu X et al (2014) P2Y13 receptor-mediated rapid increase in intracellular calcium induced by ADP in cultured dorsal spinal cord microglia. Neurochem Res 39(11):2240–50
pubmed: 25186167
doi: 10.1007/s11064-014-1426-8
Nunomura A, C R, Zhu X et al (2006) Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 65(7):631–41
pubmed: 16825950
doi: 10.1097/01.jnen.0000228136.58062.bf
Espada S, O F, Molina-Jijón E et al (2010) The purinergic P2Y(13) receptor activates the Nrf2/HO-1 axis and protects against oxidative stress-induced neuronal death. Free Radic Biol Med 49(3):416–26
pubmed: 20447456
doi: 10.1016/j.freeradbiomed.2010.04.031
Blom D, Y T, Champy MF et al (2010) Altered lipoprotein metabolism in P2Y(13) knockout mice. Biochim Biophys Acta 1801(12):1349–60
pubmed: 20817122
doi: 10.1016/j.bbalip.2010.08.013
Fabre AC, M C, Ben Addi A et al (2010) P2Y13 receptor is critical for reverse cholesterol transport. Hepatology 52(4):1477–83
pubmed: 20830789
doi: 10.1002/hep.23897
Gao ZG, D Y, Jacobson KA (2010) P2Y(13) receptor is responsible for ADP-mediated degranulation in RBL-2H3 rat mast cells. Pharmacol Res 62(6):500–5
pubmed: 20813187
pmcid: 2974784
doi: 10.1016/j.phrs.2010.08.003
Orriss I, S S, Wang N et al (2011) Bone phenotypes of P2 receptor knockout mice. Front Biosci (Schol Ed) 3(3):1038–46
pubmed: 21622253
doi: 10.2741/208
Ortega F, P.-S R, Delicado EG et al (2011) ERK1/2 activation is involved in the neuroprotective action of P2Y13 and P2X7 receptors against glutamate excitotoxicity in cerebellar granule neurons. Neuropharmacology 61(8):1210–21
pubmed: 21798274
doi: 10.1016/j.neuropharm.2011.07.010
Communi D, G N, Detheux M et al (2001) Identification of a novel human ADP receptor coupled to G(i). J Biol Chem 276(44):41479–85
pubmed: 11546776
doi: 10.1074/jbc.M105912200
Marteau F, L.P E, Communi D et al (2003) Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol 64(1):104–12
pubmed: 12815166
doi: 10.1124/mol.64.1.104
Kim YC, L J, Sak K et al (2005) Synthesis of pyridoxal phosphate derivatives with antagonist activity at the P2Y13 receptor. Biochem Pharmacol 70(2):266–74
pubmed: 15913566
pmcid: 3401943
doi: 10.1016/j.bcp.2005.04.021
Fumagalli M, T L, Lecca D et al (2004) Cloning, pharmacological characterisation and distribution of the rat G-protein-coupled P2Y(13) receptor. Biochem Pharmacol 68(1):113–24
pubmed: 15183123
doi: 10.1016/j.bcp.2004.02.038
del Puerto A, D-H J, Tapia M et al (2012) Adenylate cyclase 5 coordinates the action of ADP, P2Y1, P2Y13 and ATP-gated P2X7 receptors on axonal elongation. J Cell Sci 125(Pt 1):176–88
pubmed: 22250198
doi: 10.1242/jcs.091736
Stockwell J, J E, Cayabyab FS (2017) Adenosine A1 and A2A receptors in the brain: current research and their role in neurodegeneration. Molecules 22(4):676
pubmed: 28441750
pmcid: 6154612
doi: 10.3390/molecules22040676
Zhou LT, Le D, Kang HC et al (2023) Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer’s disease. Sci Adv 9(16):eabq7105
pubmed: 37083538
pmcid: 10121173
doi: 10.1126/sciadv.abq7105
Zhao S, U A, Wu LJ (2024) Tuning neural circuits and behaviors by microglia in the adult brain. Trends Neurosci 47(3):181–194
pubmed: 38245380
doi: 10.1016/j.tins.2023.12.003
Angulo E, C V, Mallol J et al (2003) A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. Brain Pathol 13(4):440–51
pubmed: 14655750
doi: 10.1111/j.1750-3639.2003.tb00475.x
Albasanz JL, P S, Barrachina M et al (2008) Up-regulation of adenosine receptors in the frontal cortex in Alzheimer’s disease. Brain Pathol 18(2):211–9
pubmed: 18241242
pmcid: 8095610
doi: 10.1111/j.1750-3639.2007.00112.x
Dennissen FJ, A-H M, Sydow A et al (2016) Adenosine A1 receptor antagonist rolofylline alleviates axonopathy caused by human Tau ΔK280. Proc Natl Acad Sci U S A 113(41):11597–11602
pubmed: 27671637
pmcid: 5068267
doi: 10.1073/pnas.1603119113
C RA (2005) Neuroprotection by adenosine in the brain: From A(1) receptor activation to A (2A) receptor blockade. Purinergic Sig 1(2):111–34
doi: 10.1007/s11302-005-0649-1
Giunta S, A V, Castorina A (2014) Dual blockade of the A1 and A2A adenosine receptor prevents amyloid beta toxicity in neuroblastoma cells exposed to aluminum chloride. Int J Biochem Cell Biol 54:122–36
pubmed: 25058312
doi: 10.1016/j.biocel.2014.07.009
Paul S, E P, Ishiwata K et al (2011) Adenosine A(1) receptors in the central nervous system: their functions in health and disease, and possible elucidation by PET imaging. Curr Med Chem 18(31):4820–35
pubmed: 21919845
doi: 10.2174/092986711797535335
Vanderstocken G, VdP E, Robaye B et al (2012) Protective role of P2Y2 receptor against lung infection induced by pneumonia virus of mice. PLoS One 7(11):e50385
pubmed: 23185614
pmcid: 3503929
doi: 10.1371/journal.pone.0050385
Duarte JM, G R, Caetano L et al (2019) Region-specific control of microglia by adenosine A2A receptors: uncoupling anxiety and associated cognitive deficits in female rats. Glia 67(1):182–192
pubmed: 30461068
doi: 10.1002/glia.23476
Arendash GW, S W, Rezai-Zadeh K et al (2006) Caffeine protects Alzheimer’s mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience 142(4):941–52
pubmed: 16938404
doi: 10.1016/j.neuroscience.2006.07.021
Espinosa J, R A, Nunes F et al (2013) Caffeine consumption prevents memory impairment, neuronal damage, and adenosine A2A receptors upregulation in the hippocampus of a rat model of sporadic dementia. J Alzheimers Dis 34(2):509–18
pubmed: 23241554
doi: 10.3233/JAD-111982
Arendash GW, M T, Cao C (2009) rt al, Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer’s disease mice. J Alzheimers Dis 17(3):661–80
pubmed: 19581722
doi: 10.3233/JAD-2009-1087
Temido-Ferreira M, F D, Batalha VL et al (2020) Age-related shift in LTD is dependent on neuronal adenosine A2A receptors interplay with mGluR5 and NMDA receptors. Mol Psychiatry 25(8):1876–1900
pubmed: 29950682
doi: 10.1038/s41380-018-0110-9
Viana da Silva S, H M, Zhang P et al (2016) Early synaptic deficits in the APP/PS1 mouse model of Alzheimer’s disease involve neuronal adenosine A2A receptors. Nat Commun 17(7):11915
doi: 10.1038/ncomms11915
Laurent C, B S, Ferry B et al (2016) A2A adenosine receptor deletion is protective in a mouse model of tauopathy. Mol Psychiatry 21(1):149
pubmed: 26216297
doi: 10.1038/mp.2015.115
Canas PM, P L, Cunha GM et al (2009) Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J Neurosci 29(47):14741–51
pubmed: 19940169
pmcid: 6665997
doi: 10.1523/JNEUROSCI.3728-09.2009
Dall’Igna OP, P L, Souza DO et al (2003) Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity. Br J Pharmacol 138(7):1207–9
pubmed: 12711619
doi: 10.1038/sj.bjp.0705185
Silva AC, L C, Gonçalves FQ et al (2018) Blockade of adenosine A2A receptors recovers early deficits of memory and plasticity in the triple transgenic mouse model of Alzheimer’s disease. Neurobiol Dis 117:72–81
pubmed: 29859867
doi: 10.1016/j.nbd.2018.05.024
Faivre E, C J, Zornbach K et al (2018) Beneficial effect of a selective adenosine A2A receptor antagonist in the APPswe/PS1dE9 mouse model of Alzheimer’s disease. Front Mol Neurosci 12(11):235
doi: 10.3389/fnmol.2018.00235
Gessi S, P T, Negro G et al (2021) A2A adenosine receptor as a potential biomarker and a possible therapeutic target in Alzheimer’s disease. Cells 10(9):2344
pubmed: 34571993
pmcid: 8469578
doi: 10.3390/cells10092344
Merighi S, B E, Casetta I et al (2021) Upregulation of cortical A2A adenosine receptors is reflected in platelets of patients with Alzheimer’s disease. J Alzheimers Dis 80(3):1105–1117
pubmed: 33646165
doi: 10.3233/JAD-201437
Huang Q, Y J, Yu W et al (2024) P2X7 Receptor: an emerging target in Alzheimer’s disease. Mol Neurobiol 61(5):2866–2880
pubmed: 37940779
doi: 10.1007/s12035-023-03699-9
Janssen B, M R (2019) Development of brain PET imaging agents: strategies for imaging neuroinflammation in Alzheimer’s disease. Prog Mol Biol Transl Sci 165:371–399
pubmed: 31481170
doi: 10.1016/bs.pmbts.2019.04.005